# TARA catalysts: Protara Therapeutics, Inc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/tara/catalysts

> Protara Therapeutics, Inc. (TARA) has 7 upcoming catalysts. The next is the TARA-002 primary completion, December 2026.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, quarter only, exact day, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | Protara Therapeutics, Inc. |
| Ticker | TARA (Nasdaq) |
| SEC CIK | 1359931 |
| SIC | 2836 |
| SEC filings | https://sec-api.dev/companies/tara |

## Cash runway

Cash $143.1M as of 2026-09-30; quarterly burn $18.4M; about 23.3 months of runway at that rate (XBRL company facts, accession 0001213900-26-116612).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Oct 2023 | [TARA-002 trial start](https://sec-api.dev/pdufa/tara-002) | TARA | macrocystic and mixed-cystic LMs | completed | "In October 2023, we initiated the STARBORN-1 trial, a Phase 2 single arm, open-label clinical trial to evaluate the safety and efficacy of TARA-002 in approximately 30 pediatric patients ages six months to less than 18 years old with macrocystic and mixed-cystic LMs." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1359931/000121390026025433/ea0277639-10k_protara.htm)) |
| Q4 2024 | [TARA-002 interim data readout](https://sec-api.dev/pdufa/tara-002) | TARA | non-muscle invasive bladder cancer | scheduled | "On track to report interim data in six-month evaluable patients in ADVANCED-2 trial of TARA-002 in NMIBC in 4Q 2024" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1359931/000121390024096243/ea021925801ex99-1_protara.htm)) |
| November 12, 2024 | [Protara Therapeutics, Inc. earnings report](https://sec-api.dev/companies/tara/catalysts) | TARA |  | completed | "Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today provided a business update and announced financial results for the third quarter ended September 30, 2024." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1359931/000121390024096243/ea021925801ex99-1_protara.htm)) |
| Dec 2024 | [TARA-002 interim data readout](https://sec-api.dev/pdufa/tara-002) | TARA |  | completed, positive | "December 2024, the Company reported positive interim results from its ongoing Phase 2 open-label" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1359931/000121390025003026/ea022745701ex99-2_protara.htm)) |
| Q1 2025 | [TARA-002 trial start](https://sec-api.dev/pdufa/tara-002) | TARA |  | delayed | "The Company expects to begin dosing patients in the THRIVE-3 registrational trial in the first quarter of 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1359931/000121390024096243/ea021925801ex99-1_protara.htm)) |
| 1H 2025 | [TARA-002 interim data readout](https://sec-api.dev/pdufa/tara-002) | TARA |  | scheduled | "Finally, we continue to expect interim data in the first half of 2025 from our ongoing Phase 2 STARBORN-1 trial of TARA-002 in lymphatic malformations (LMs), a rare condition primarily impacting children for which there are no FDA approved therapies."" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1359931/000121390024096243/ea021925801ex99-1_protara.htm)) |
| March 5, 2025 | [Protara Therapeutics, Inc. earnings report](https://sec-api.dev/companies/tara/catalysts) | TARA |  | completed | "Protara Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1359931/000121390025020366/ea023264101ex99-1_protara.htm)) |
| May 8, 2025 | [Protara Therapeutics, Inc. earnings report](https://sec-api.dev/companies/tara/catalysts) | TARA |  | completed | "Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced financial results for the first quarter ended March 31, 2025, and provided a business update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1359931/000121390025040809/ea024092901ex99-1_protara.htm)) |
| August 11, 2025 | [Protara Therapeutics, Inc. earnings report](https://sec-api.dev/companies/tara/catalysts) | TARA |  | completed | "Therapeutics Announces Second Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1359931/000121390025073937/ea025050901ex99-1_protara.htm)) |
| late 2025 | [TARA-002 trial start](https://sec-api.dev/pdufa/tara-002) | TARA |  | scheduled | "The Company now expects to initiate dosing in THRIVE-3, a registrational Phase 3 clinical trial, by the end of 2025 due to administrative and funding challenges in academic sites in the U.S." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1359931/000121390025107873/ea026318301ex99-1_protara.htm)) |
| Q4 2025 | [TARA-002 interim data readout](https://sec-api.dev/pdufa/tara-002) | TARA |  | scheduled | "Results from an interim analysis in the Phase 2 STARBORN-1 trial of TARA-002 in pediatric LMs patients remain on track for 4Q 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1359931/000121390025107873/ea026318301ex99-1_protara.htm)) |
| November 10, 2025 | [Protara Therapeutics, Inc. earnings report](https://sec-api.dev/companies/tara/catalysts) | TARA |  | completed | "Therapeutics, Inc. (Nasdaq: TARA) ("Protara" or the "Company"), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced financial results for the third quarter ended September" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1359931/000121390025107873/ea026318301ex99-1_protara.htm)) |
| November 19, 2025 | [TARA-002 interim data readout](https://sec-api.dev/pdufa/tara-002) | TARA |  | completed, positive | "TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced positive interim results from its ongoing Phase 2 open-label STARBORN-1 trial assessing intracystic injection of TARA-002, the Company's investigational cell-based therapy, in pediatric patients with macrocystic and mixed cystic lymphatic malformations (LMs)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1359931/000121390025112383/ea026638401ex99-2_protara.htm)) |
| December 4, 2025 | [TARA-002 interim data readout](https://sec-api.dev/pdufa/tara-002) | TARA |  | completed, positive | "December 4, 2025, we presented updated interim data from our ongoing Phase 2 open-label ADVANCED-2 Trial of TARA-002 in patients with carcinoma in situ or CIS (± Ta/T1) NMIBC at a poster session at the 2025 Annual Meeting of the Society of Urologic Oncology (SUO) Conference, reporting positive results that continue to support TARA-002's potential as a mainstay in the NMIBC treatment landscape and demonstrating meaningful and durable activity in BCG-Na&iuml;ve NMIBC patients." ([SEC prospectus (424B)](https://www.sec.gov/Archives/edgar/data/1359931/000121390025118744/ea0268632-424b5_protara.htm)) |
| February 27, 2026 | [TARA-002 interim data readout](https://sec-api.dev/pdufa/tara-002) | TARA | carcinoma in situ or CIS | scheduled | "On February 27, 2026, the Company will present updated interim data from its ongoing Phase 2 open-label ADVANCED-2 Trial of TARA-002 in patients with carcinoma in situ or CIS (± Ta/T1)" ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1359931/000121390026019617/ea0277972-8k_protara.htm)) |
| March 10, 2026 | [Protara Therapeutics, Inc. earnings report](https://sec-api.dev/companies/tara/catalysts) | TARA |  | completed | "Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1359931/000121390026025432/ea028040401ex99-1.htm)) |
| May 13, 2026 | [Protara Therapeutics, Inc. earnings report](https://sec-api.dev/companies/tara/catalysts) | TARA |  | completed | "Therapeutics Announces First Quarter 2026 Financial Results and Provides a Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1359931/000121390026055462/ea028858101ex99-1.htm)) |
| 2H 2026 | [TARA-002 trial start](https://sec-api.dev/pdufa/tara-002) | TARA |  | scheduled | "We remain on track to complete enrollment in our BCG-Unresponsive registrational cohort in the ADVANCED-2 trial and to initiate the ADVANCED-3 registrational trial in BCG-Na&iuml;ve patients in the second half of 2026."" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1359931/000121390026025432/ea028040401ex99-1.htm)) |
| August 11, 2026 | [Protara Therapeutics, Inc. earnings report](https://sec-api.dev/companies/tara/catalysts) | TARA |  | completed | "Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1359931/000121390026087506/ea029923601ex99-1.htm)) |
| Q4 2026 | [TARA-002 interim data readout](https://sec-api.dev/pdufa/tara-002) | TARA |  | scheduled | "THRIVE-3, the Company's registrational Phase 3 clinical trial, is ongoing, and the Company expects to report interim results in the fourth quarter of 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1359931/000121390026087506/ea029923601ex99-1.htm)) |
| November 6, 2026 | [Protara Therapeutics, Inc. earnings report](https://sec-api.dev/companies/tara/catalysts) | TARA |  | completed | "Therapeutics Announces Third Quarter 2026 Financial Results and Provides a Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1359931/000121390026116607/ea030956701ex99-1.htm)) |
| December 2026 | [TARA-002 primary completion](https://sec-api.dev/pdufa/tara-002) | TARA | Lymphatic Malformation | scheduled | "NCT05871970 (Safety and Efficacy Study of Intracystic TARA-002 for the Treatment of Lymphatic Malformations in Participants 6 Months to Less Than 18 Years of Age): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Protara Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05871970)) |
| Dec 2026 to Mar 2027 | [TARA-002 topline data readout](https://sec-api.dev/pdufa/tara-002) | TARA | Lymphatic Malformation | scheduled | "NCT05871970 (Safety and Efficacy Study of Intracystic TARA-002 for the Treatment of Lymphatic Malformations in Participants 6 Months to Less Than 18 Years of Age): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Protara Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05871970)) |
| 2H 2027 | [TARA-002 NDA/BLA submission](https://sec-api.dev/pdufa/tara-002) | TARA |  | scheduled | "Enrollment in registrational STARBORN-1 trial now expected to complete in early 1Q'2027; expect to initiate a rolling BLA submission for TARA-002 in LMs in 2H 2027" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1359931/000121390026116607/ea030956701ex99-1.htm)) |
| March 2028 | [Choline chloride for injection primary completion](https://sec-api.dev/pdufa/choline) | TARA | Choline Deficiency; Liver Injury | scheduled | "NCT06910943 (Study of Choline Chloride for Injection in Adolescent and Adult Patients With Intestinal Failure Receiving Long Term Parenteral Support): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2028-03 (ESTIMATED); Lead Sponsor Protara Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06910943)) |
| Mar to Jun 2028 | [Choline chloride for injection topline data readout](https://sec-api.dev/pdufa/choline) | TARA | Choline Deficiency; Liver Injury | scheduled | "NCT06910943 (Study of Choline Chloride for Injection in Adolescent and Adult Patients With Intestinal Failure Receiving Long Term Parenteral Support): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2028-03 (ESTIMATED); Lead Sponsor Protara Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06910943)) |
| April 2028 | [TARA-002 primary completion](https://sec-api.dev/pdufa/tara-002) | TARA |  | scheduled | "NCT07480356 (Efficacy and Safety of Intravesical TARA-002 Compared With Investigator's Choice of Intravesical Chemotherapy in Participants With BCG-naïve High-grade Non-muscle Invasive Bladder Cancer): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-04 (ESTIMATED); Lead Sponsor Protara Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07480356)) |
| Apr to Jul 2028 | [TARA-002 topline data readout](https://sec-api.dev/pdufa/tara-002) | TARA |  | scheduled | "NCT07480356 (Efficacy and Safety of Intravesical TARA-002 Compared With Investigator's Choice of Intravesical Chemotherapy in Participants With BCG-naïve High-grade Non-muscle Invasive Bladder Cancer): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-04 (ESTIMATED); Lead Sponsor Protara Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07480356)) |

## Drugs

- [Choline chloride for injection](https://sec-api.dev/pdufa/choline): Choline Deficiency
- [TARA-002](https://sec-api.dev/pdufa/tara-002): carcinoma in situ or cis, macrocystic and mixed cystic lms, cancer and rare diseases, today, macrocystic and mixed-cystic lms, non-muscle invasive bladder cancer, Bladder (Urothelial, Transitional Cell) Cancer, Lymphatic Malformation

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/tara/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "TARA catalysts: Protara Therapeutics, Inc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/tara/catalysts

```bibtex
@misc{secapidev_companies_tara_catalysts_20261116,
  title        = {TARA catalysts: Protara Therapeutics, Inc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/tara/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_tara_catalysts_20261116","title":"TARA catalysts: Protara Therapeutics, Inc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/tara/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
